布比卡因故事:致敬乔治·A·奥尔布赖特(1931-2020)
本文回顾了1979年George A. Albright在《Anesthesiology》发表的社论,提出布比卡因心脏毒性问题,尽管初期遭科学界抵制,但最终促成多项麻醉学进展,包括FDA黑框警告、实验室研究证实心脏毒性、开发罗哌卡因等更安全药物以及脂肪乳剂治疗局麻药毒性。时任主编C. Philip Larson, Jr提供独特视角。
要点
- Albright的社论引发对布比卡因心脏毒性的关注,推动后续研究。
- FDA曾对0.75%布比卡因用于产科麻醉发出黑框警告,持续至1999年。
- 该事件促进了罗哌卡因等更安全局麻药和脂肪乳剂疗法的出现。
核心结论
- Albright的社论虽初期受抵制,但最终导致布比卡因心脏毒性被证实及多项麻醉学进步。
研究设计与样本
- 本文为历史回顾性文章,由时任《Anesthesiology》主编C. Philip Larson, Jr撰写,讲述布比卡因故事。
主要发现
- 1979年Albright发表社论提出布比卡因心脏毒性问题。
- 1983年FDA发布黑框警告,建议产科麻醉避免使用0.75%布比卡因,该警告持续至1999年。
- 社论促成实验室研究证实布比卡因心脏毒性、开发罗哌卡因等 stereoselective 药物以及接受脂肪乳剂治疗局麻药毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 1979, George A. Albright, MD (1931-2020) published a controversial editorial in Anesthesiology that raised the question of bupivacaine cardiotoxicity. In it, he presented several cases of rapid cardiovascular collapse after administration of the highly lipophilic local anesthetic and called for further investigation. Although the scientific community initially resisted Dr Albright's idea, his editorial would ultimately lead to several important advancements in anesthesiology. In 1983, the US Food and Drug Administration issued a black box warning that recommended against the use of 0.75% bupivacaine in obstetric anesthesia. This warning would remain in place until 1999. In addition, Dr Albright's article led to the following changes: laboratory research that proved the cardiotoxicity of bupivacaine; the development of safer, stereoselective agents like ropivacaine; and the acceptance of lipid emulsion as a treatment for local anesthetic toxicity. In this article, C. Philip Larson, Jr, MDCM, Editor-in-Chief of Anesthesiology at the time of publication of Albright's manuscript, provides a unique perspective on the bupivacaine story.
引用
- Larson CP, Youssefzadeh K, Moon JS, et al. The Bupivacaine Story: A Tribute to George A. Albright, MD (1931-2020). Anesth Analg. 2022. PMID: 35924832. doi:10.1213/ANE.0000000000006161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。